Telix to Showcase Innovation in Urology at AUA Annual Meeting, including New ZIRCON Phase III Data in Very Small Renal Masses

Melbourne (Australia) | 27 April 2023

Telix will showcase further detailed analyses from the Company’s completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) ( Identifier: NCT03849118) in a late-breaking oral presentation at the American Urological Association (AUA) Annual Meeting being held in Chicago from 28 April to 1 May 2023.

New ZIRCON data:

Associate Professor Brian Shuch, MD, Director, Kidney Cancer Program, UCLA Institute of Urologic Oncology (Los Angeles, California) and a Principal Investigator in the ZIRCON study will present new data on renal masses 2cm and smaller (a secondary endpoint).

Telix in-booth Theatre:

In addition, the Company will be presenting a series of thought leadership sessions in Telix’s in-booth theatre (at booth #1655), featuring key opinion leaders in urologic oncology and theranostics (therapeutic and diagnostic radiopharmaceuticals).

Dr Colin Hayward, Telix Chief Medical Officer, stated, “Telix’s vision in urology is to support the patient across the continuum of imaging, surgery and therapy. We are therefore pleased to be at AUA, the largest gathering of urologists worldwide, presenting further detail on the highly successful ZIRCON study, and also running our own series of lectures from key opinion leaders, including sessions on prostate-specific membrane antigen (PSMA)- and carbonic anhydrase IX- (CAIX)-targeting theranostics. We look forward to seeing you at booth #1655 where we will be delighted to introduce Telix’s deep urologic pipeline, and provide insight into the clinical utility of our approved gallium-based PSMA-PET imaging agent, Illuccix®.”

AUA presentation details are as follows (all times CDT):

Session: LBA03: Late-Breaking Abstracts III – Cancer

Title: 89Zr-DFO-girentuximab for PET/CT Imaging of Indeterminate Renal Masses – Results from Phase III ZIRCON Study

Date and Time: Sunday, April 30, 3:40pm

Presenter: Associate Professor Brian Shuch (UCLA)

Telix in-booth theatre highlights (booth #1655):

Date and Time: Friday, April 28, 9:30am

Title: New Frontiers: ZIRCON Phase Ill Study Top-Line Data

Presenter: Neeta Pandit-Taskar, MD, Memorial Sloan Kettering Cancer Center, New York

Date and Time: Friday, April 28, 12:00pm

Title: Patient Selection: What the Urologist needs to know about Lutetium PSMA Radioligand Therapy

Presenter: Pedro C. Barata, MD, MSc, University Hospitals Seidman Cancer Center, Cleveland

Date and Time: Friday, April 28, 3:00pm and Saturday, April 29, 1.30pm

Title: PSMA Image Reading for Urologists

Presenter: Jaideep S. Sohi MD, President and Founder, American Molecular Imaging

Date and Time: Sunday, April 30, 10:00am

Title: New Frontiers: Therapeutic Targeting of PSMA with Antibody vs Small Molecule

Presenter: Scott T. Tagawa, MD, MS, FASCO, FACP, Weill Cornell Medicine, New York

For full in-booth theatre listings and to secure a seat, please visit Telix’s medical education website: Space is limited so early registration is recommended.